AgeX Therapeutics, Inc. (AGE): Price and Financial Metrics
AGE Price/Volume Stats
| Current price | $11.10 | 52-week high | $35.71 |
| Prev. close | $12.60 | 52-week low | $11.07 |
| Day low | $11.10 | Volume | 3,700 |
| Day high | $12.59 | Avg. volume | 3,849 |
| 50-day MA | $14.16 | Dividend yield | N/A |
| 200-day MA | $20.41 | Market Cap | 11.97M |
AGE Stock Price Chart Interactive Chart >
AgeX Therapeutics, Inc. (AGE) Company Bio
AgeX Therapeutics, Inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the United States. The company's lead cell-based therapeutic candidates in development include AGEX-BAT1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as Type II adult-onset diabetes; and AGEX-VASC1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. Its lead drug-based therapeutic candidate in discovery is AGEX-iTR1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. In addition, the company markets human embryonic stem cells; and GeneCards Database Suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. AgeX Therapeutics, Inc. has a research collaboration with the University of California, Irvine on neural stem cell research program for Huntington's disease and other neurological disorders; and Sernova Corp. The company was founded in 2017 and is based in Alameda, California.
AGE Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | -22.30% |
| 3-year | -60.14% |
| 5-year | -79.28% |
| YTD | -19.27% |
| 2023 | -30.24% |
| 2022 | -49.37% |
| 2021 | -28.29% |
| 2020 | -16.48% |
| 2019 | -39.13% |
Loading social stream, please wait...